• 1

Andrew Smith
Management Director and COO

Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving lives of patients whose infections may otherwise may be inadequately treated

About us - Team

  • All
  • ALLECRA Team
  • Philipp Knechtle,



    Ph.D., Biozentrum, University of Basel; Postdoc, Institut Pasteur, Paris. Philipp has 18 years experience in microbiology with over 10 years in biotech companies. Previous roles include Junior Group Leader in Microbial Mechanisms of Pathogenicity at the Biozentrum, University of Basel; Group Leader Discovery and Development at Evolva SA; and Group Leader/Project Manager Antifungals at Polyphor Ltd. Philipp has further co-founded the Swiss antimicrobial start-up Selmod Gmbh where he was responsible Research and Development.

    • ALLECRA Team
  • Jorge Vigueras,

    Clinical Trial Manager


    Jorge Vigueras, has a B.B.A. from Universidad Anáhuac del Sur, Mexico and Centro Universitario Francisco de Vitoria, Madrid, Spain. He has over 16 years’ experience in pharma, CRO and biotech companies managing clinical trial protocols development processes and leading internal teams and vendors, having ensured all trial deliverables were met according to timelines, budget, quality standards and operational procedures. Roles in drug development and clinical research have included CRA in Mexico at Eli Lilly and Schering-Plough, Regional LATAM Project Manager at PPD, Regional LATAM Clinical Trial Manger at ICON, Global Sr. Clinical Project Manager at Novartis. More recently he was Global Clinical Project Manager at AB Science in Paris, France.

    • ALLECRA Team
  • Paola Motta,

    DMPK Director


    B.A., Ph.D. Alma Mater Studiorum Bologna, Italy; M.B.A. University of Lausanne, Switzerland. Paola has 20 years of experience of drug Research and Development within the pharmaceutical industry, the majority of which was spent in the DMPK Department of GlaxoSmithKline. Paola has gained significant expertise in the pre-clinical safety aspects of clinical drug development during her career.

    • ALLECRA Team
  • Patrick Velicitat

    Chief Medical Officer


    MD graduated from Paris VII University, Xavier Bichat Medical School, with 30 years of experience in Clinical development, Pharmacovigilance and Medical Affairs. It includes, within Boehringer Ingelheim, roles as Head of Medical Affairs and Pharmacovigilance in France, Regional Head of Clinical research in Asia and Head of Clinical Operations in Japan.

    • ALLECRA Team
  • Andrew Smith,

    Management Director and COO


    FCMA, CGMA. Andrew has over 30 years’ experience in finance within the pharma and medical device industry as well as in public accounting. He served as Vice President Finance and Chief Financial Officer of Sucampo Pharmaceuticals Inc between 2011 – 2017 and has held other management positions with a number of other companies within Europe, Asia and USA. He is a Fellow of the Institute of Management Accountants and a Chartered Global Management Accountant and has studied business and accounting at Liverpool John Moore’s University and Durham University Business School.

    • ALLECRA Team
  • Brice R. Suire,

    Finance Director


    Master in Finance Paris Dauphine, CPA, IEP Insead. Brice has 25 years’ experience in finance. He worked over 15 years at Novartis in Finance positions of increasing responsibility. Brice played a significant role in establishing the Novartis Institute for Biomedical Research in Cambridge, MA, where he worked as Head of Finance for Research Collaborations, getting exposed to strategic alliances with biotech companies and Global Head of Financial Reporting and Accounting for Research (6 sites). Brice started his career with Audit Consultancy firms Mazars in Paris and London and Price Waterhouse Coopers in Madrid

    • ALLECRA Team
Between them, the Allecra team has more than 150 years’ experience in bringing innovative pharmaceutical products to patients and doctors. Much of that experience is focussed on novel antibiotics which may be effectively used against a broad range of pathogens including multi-drug-resistant bacteria

Allecra Therapeutics

a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections Allecra has a novel β-lactamase inhibitor in Phase 3 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world

Scientific Information

Journal Publications


Conference Poster  


Allecra Therapeutics GmbH
Im Kränzliacker 9
79576 Weil am Rhein


Allecra Therapeutics SAS
10 rue Alexandre Freund
68300 Saint-Louis France
Tel +33 3 8968 9876


If you have any questions about our work,
please feel free to contact us.

All rights reserved
Copyright 2018
Allecra Therapeutics SAS